Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FD-001 in R/R Hematological Malignancies
NCT06731699Phase 1Recruiting
- Sponsor
- Chengdu FenDi Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FD-001 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Chengdu FenDi Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 32 days, Maximum Tolerated Dose at 32 days and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
FD-001
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06731699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731699.